<DOC>
	<DOCNO>NCT00959010</DOCNO>
	<brief_summary>Essential fatty acid ( EFA ) deficiency often report patient cystic fibrosis ( CF ) , particularly homozygous DF508 mutation . Clinical symptom CF may influence correct EFA deficiency . Nevertheless , value EFA supplementation CF remain controversial . Within multicentric international randomize placebo-controlled trial evaluate , accord recommendation Cochrane analysis , beneficial effect oral supplementation polyunsaturated fatty acid select biochemical functional outcome parameter inflammatory biomarkers , incorporation cell membrane phospholipid , lung function , exercise tolerance , clinical nutritional status property transepithelial ion transport . The study undertaken cohort CF patient age 6 year old ( 60 patient ) , homozygous DF508 mutation treat Azithromycine . Supplementation perform triglyceride source daily dose 60 mg/kg omega-3 polyunsaturated fatty acid ( Omega 3 Premium√¢ , Laboratoires Ponroy , France ) . Before enrolled trial study , patient undergo nutritional assessment evaluation total fat dietary intake overall calorie intake use 3-days diet record food frequency questionnaire . Plasma erythrocyte membrane EFA profile inflammatory marker monitor baseline condition , 3 , 6 12 month start treatment . Lung function perform patient visit exercise test do end treatment . Properties ion transport search sweat test end treatment .</brief_summary>
	<brief_title>Omega 3 Supplementation Cystic Fibrosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>1 . Male female patient 6 year age visit 1 stable cystic fibrosis 2 . Documented Homozygous DeltaF508 mutation 3 . Patient treat stable dose Azithromycine since least 3 month 4 . Able perform pulmonary function test swallow capsule 5 . Female patient childbearing potential must negative serum pregnancy test prior enrolment must agree practice effective birth control study 6 week thereafter 6 . Signed informed consent obtain patient , case patient minor , patient 's legally acceptable representative ( parent guardian ) accord ICH &amp; local regulation . Child assent nevertheless obtain 1 . Ongoing acute illness include acute upper low respiratory infection within 2 week baseline evaluation . 2 . Abnormalities screen chest xray ( CTscan ) suggest clinically active pulmonary disease CF , new , significant abnormality atelectasis pleural effusion may indicative clinically active pulmonary involvement secondary CF . 3 . Any chronic ( &gt; 1 week daily ) oral intravenous inflammatory treatment , Azithromycine , give patient within 3 month start study treatment . 4 . Active bleeding increase risk bleeding ( rate platelet &lt; 50,000/mm3 , patient treatment anticoagulant antiplatelet agent , disturbance haemostasis PTT &lt; 70 % , bleed disorder ) . 5 . Patient significant liver disease , define elevate liver function test value 2fold high upper normal range investigational local lab abnormal ultrasound sign cirrhosis . 6 . Hypercholesterolemia ( &gt; 240mg % ) . 7 . Patient pregnant breastfeeding mother 8 . Patient participate participate another investigational drug trial receive receive investigational drug within last 28 day entry study . 9 . Patient unlikely comply visit schedule protocol enable follow study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Omega 3</keyword>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Inflammatory marker</keyword>
</DOC>